PRESS RELEASE published on 12/20/2024 at 15:15, 1 year 10 months ago Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency Quantum BioPharma Ltd. purchases $1,000,000 Bitcoin and other cryptocurrencies, allows cryptocurrency transactions, emphasizing compliance and potential returns for shareholders Bitcoin Compliance Investment Cryptocurrency Quantum BioPharma
BRIEF published on 12/14/2024 at 01:05, 1 year 11 months ago Quantum BioPharma conclut la première tranche de son offre Première Tranche Biopharmacie Quantique Unités D'obligations Développement Du Capital Dollars Canadiens
BRIEF published on 12/14/2024 at 01:05, 1 year 11 months ago Quantum BioPharma Concludes Initial Tranche of Offering First Tranche Capital Development Quantum BioPharma Canadian Dollars Debenture Units
PRESS RELEASE published on 12/14/2024 at 01:00, 1 year 11 months ago Quantum Biopharma Announces Closing of First Tranche Quantum BioPharma closes initial tranche of offering, issuing 500 Debenture Units for $500,000. Proceeds for business development and working capital. Securities subject to statutory hold period Working Capital Statutory Hold Period Quantum BioPharma Debenture Units Tranche Offering
BRIEF published on 12/10/2024 at 13:35, 1 year 11 months ago Quantum Biopharma avance dans l'essai clinique Lucid-MS Recherche Biopharmaceutique Biopharmacie Quantique Examen De Sécurité Essai Lucid-MS Progrès Clinique
BRIEF published on 12/10/2024 at 13:35, 1 year 11 months ago Quantum Biopharma Moves Forward in Lucid-MS Clinical Trial Biopharmaceutical Research Quantum BioPharma Lucid-MS Trial Clinical Advancement Safety Review
PRESS RELEASE published on 12/10/2024 at 13:30, 1 year 11 months ago Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS) Quantum BioPharma announces approval to proceed with dosing of second cohort in Lucid-21-302 trial. Company focused on innovative treatments for neurodegenerative disorders Drug Development Neurodegenerative Disorders Quantum BioPharma Lucid-21-302 Trial Safety Review Committee
BRIEF published on 12/05/2024 at 13:35, 1 year 11 months ago Quantum BioPharma Launches Private Placement for $5 Million Private Placement Convertible Debenture Canadian Market Investment Offering Quantum BioPharma
BRIEF published on 12/05/2024 at 13:35, 1 year 11 months ago Quantum BioPharma lance un placement privé de 5 millions de dollars Placement Privé Marché Canadien Obligation Convertible Biopharmacie Quantique Offre D'investissement
PRESS RELEASE published on 12/05/2024 at 13:30, 1 year 11 months ago Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million Quantum BioPharma announces a non-brokered private placement offering of convertible debenture units. Proceeds for business development and working capital Private Placement Working Capital Business Development Quantum BioPharma Debenture Units
Published on 11/18/2026 at 14:30, 41 minutes ago Boron One Announces Non-Binding Heads of Agreement with Multinational Manufacturing Company
Published on 11/18/2026 at 13:35, 1 hour 36 minutes ago ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
Published on 11/18/2026 at 13:30, 1 hour 41 minutes ago NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
Published on 11/18/2026 at 13:20, 1 hour 51 minutes ago Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
Published on 11/18/2026 at 13:00, 2 hours 11 minutes ago Silver Storm to Attend the 121 Mining Investment Conference in London, UK
Published on 11/18/2026 at 15:05, 6 minutes ago Introducing Cognizant® Patient Hub Operations: AI-enabled patient access offering designed to shorten the path from prescription to therapy
Published on 11/18/2026 at 15:04, 7 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group PLC
Published on 11/18/2026 at 07:45, 7 hours 26 minutes ago Successful pricing of US$ 10 billion of bonds as part of the financing of the PTC acquisition
Published on 11/18/2026 at 07:45, 7 hours 26 minutes ago Succès de l’émission obligataire de 10 milliards dollars américains dans le cadre du financement de l’acquisition de PTC